【券商聚焦】花旗大幅上调药明康德目标价 将其列为CDMO首选

金吾财讯
30 Jul

金吾财讯 | 花旗报告指,药明康德(02359)管理层上调2025年指引,主要是由于产能快速扩张,而非关税战前的订单激增。持续经营业务收入预计达到425至435亿元人民币,按年增长13%至17%(此前指引为415至430亿元人民币,按年增长10%至15%)。管理层预期2025年下半年持续经营业务收入将实现按年及较上半年双位数增长,全年新指引意味按年增长5%至10%、较上半年增长6%至11%。管理层...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10